News
Current position:Product Center > Cell lines > Immune checkpoints > CD40 > H_CD40(TNFRSF5) Reporter Jurkat Cell Line
H_CD40(TNFRSF5) Reporter Jurkat Cell Line
Description
Cat. No: GM-C09520
Product: H_CD40(TNFRSF5) Reporter Jurkat Cell Line


CD40 is a key cell surface receptor in the TNF receptor superfamily, primarily found on B cells, dendritic cells, macrophages, and some endothelial cells. Its main role is to regulate immune responses by promoting B cell proliferation, differentiation, and antibody production. When it binds to its ligand CD40L (expressed by activated T cells), CD40 activates various signaling pathways that enhance immune function.

CD40 signaling occurs through multiple pathways activated upon CD40L binding, including NF-Κb, MAPK (ERK, JNK, p38 MAPK), and PI3K/Akt. This activation triggers biological responses such as cell proliferation, survival, cytokine secretion, and immune memory formation, making CD40 crucial for regulating immune responses and maintaining immune tolerance.

H_CD40(TNFRSF5) Reporter Jurkat Cell Line is a clonal stable Jurkat cell line constructed using lentiviral technology, constitutive expression of the CD40 gene, along with signal-dependent expression of a luciferase reporter gene. When CD40L binds to CD40, it activates downstream signaling pathways, leading to the expression of luciferase. Blockade antibodies can inhibit this signal transmission. The luciferase activity measurement indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of drugs related to CD40.
Data
Response to Human CD40L Protein. The H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well (96-well format) was stimulated with serial dilutions of Human CD40L Protein (Cat. GM-84919RP) in assay buffer (RPMI 1640 + 1% FBS + 1% P.S) for 6 hours. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The maximum induction fold was approximately [71.7]. Data are shown by drug mass concentration.
Response to Anti-H_CD40L hIgG1 Antibody(dapirolizumab). Serial dilutions of Anti-H_CD40L hIgG1 Antibody(dapirolizumab) (Cat. GM-83977AB) was incubated with 100 ng/well of Human CD40L Protein (Cat. GM-84919RP) for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). After pre-incubation, add the mixture to the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a density of 1E5 cells/well in a 96-well format, and incubate for 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The results indicated maximum blocking folds of approximately [61.2]. Data are shown by drug mass concentration.
Response to Anti-H_CD40L hIgG1 Antibody(dapirolizumab). Serial dilutions of the Anti-H_CD40L hIgG1 Antibody(dapirolizumab) (Cat. GM-83977AB) was incubated with 1E4 cells/well of the H_CD40L CHO-K1 Cell Line (Cat. GM-C35532) in a 96-well plate for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). Subsequently, the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well was added, and the coculture proceeded for an additional 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The results indicated maximum blocking folds of approximately [45.2]. Data are shown by drug mass concentration.
Response to Anti-H_CD40 hIgG1 Antibody(ravagalimab). Serial dilutions of the Anti-H_CD40 hIgG1 Antibody(ravagalimab) (Cat. GM-86199AB) was incubated with 1E5 cells/well of the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) in a 96-well plate for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). Subsequently, the Human CD40L Protein (Cat. GM-84919RP) at a concentration of 50 ng/well was added, and the coculture proceeded for an additional 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The results indicated maximum blocking folds of approximately [14.3]. Data are shown by drug mass concentration.
Response to Anti-H_CD40 hIgG1 Antibody(ravagalimab). H_CD40L CHO-K1 Cell Line (Cat. GM-C35532) was seeded at a density of 1E4 cells per well in a 96-well plate and incubated overnight. The next day, serial dilutions of the Anti-H_CD40 hIgG1 Antibody(ravagalimab) (Cat. GM-86199AB) were incubated with 1E5 cells/well of the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) in a 96-well plate for 1 hour, and then added to the pre-seeded cells. The mixture was incubated for an additional 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The results indicated maximum blocking folds of approximately [41.3]. Data are shown by drug mass concentration
Response to Anti-H_CD40 hIgG1 Antibody(APX005M). The H_FCGR2B (CD32B) CHO-K1 Cell Line (Cat. GM-C16925) and the CHO-K1 Cell Line were seeded at a density of 1E4 cells per well in a 96-well plate and incubated overnight. The next day, serial dilutions of Anti-H_CD40 hIgG1 Antibody(APX005M) Cat. GM-24025AB) and the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells per well were added to the pre-seeded cells. The mixture was incubated for an additional 6 hours. Firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The maximum induction fold was approximately [50.5 and 6.7]. Data are presented based on drug mass concentration.
The passage stability of response to Human CD40L Protein. The passage 4, 14 and 24 of H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well (96-well format) were stimulated with serial dilutions of Human CD40L Protein (Cat. GM-84919RP) in assay buffer (RPMI 1640 + 1% FBS + 1% P.S) for 6 hours. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). Data are shown by drug mass concentration.
H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) was determined by flow cytometry using Anti-H_CD40 hIgG1 Antibody(APX005M) (Cat. GM-24025AB).
H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) was determined by flow cytometry using Anti-H_CD40L hIgG1 Antibody(dapirolizum) (Cat. GM-83977AB).
Specifications
Cat. NoGM-C09520
ProductH_CD40(TNFRSF5) Reporter Jurkat Cell Line
Product Format1 vial of frozen cells
Quantity5E6 Cells per vial,1 mL
Storage ConditionsLiquid nitrogen immediately upon receipt
Recovery MediumRPMI 1640 +10% FBS +1% P.S
Growth mediumRPMI 1640 +10% FBS +1% P.S+3.5 μg/mL Blastincidin+0.75 μg/mL Puromycin
NoteNone
Freezing Medium90%FBS+10% DMSO
Growth propertiesSuspension
Growth Conditions37°C, 5% CO₂
Safety considerationsBiosafety Level 2
Mycoplasma TestingThe cell line has been screened to confirm the absence of Mycoplasma species.
Materials
ReagentOrdering Information
RPMI 1640VivaCell/C3010-0500
Fetal Bovine SerumCegrogen biotech/A0500-3010
Pen/StrepThermo/15140-122
BlasticidinGenomeditech/GM-040404
PuromycinGenomeditech/GM-040401
H_CD40L CHO-K1 Cell LineGenomeditech/GM-C35532
H_FCGR2B(CD32B) CHO-K1 Cell LineGenomeditech/GM-C16925
Human CD40L Protein; His TagGenomeditech/GM-84919RP
Anti-H_CD40L hIgG1 Antibody(dapirolizumab)Genomeditech/GM-83977AB
Anti-H_CD40 hIgG1 Antibody(ravagalimab)Genomeditech/GM-86199AB
Anti-H_CD40 hIgG1 Antibody(APX005M)Genomeditech/GM-24025AB
GMOne-Step Luciferase Reporter Gene Assay KitGenomeditech/GM-040503
Cell Culture

Cell Recovery

Recovery Medium: RPMI 1640 +10% FBS +1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium. And spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend cell pellet with the recommended complete medium. And dispense the suspension into 1 - 2 T-25 culture flasks.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90%FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: RPMI 1640 +10% FBS +1% P.S+3.5 μg/mL Blastincidin+0.75 μg/mL Puromycin

Approximately 48-72 hours after the initial thawing, the cells can be passaged for the first time. After this initial passage, the culture medium can be adjusted to growth medium supplemented with antibiotics. If cells are not passaged within 48 hours, it is recommended to add some fresh recovery medium and place the flask horizontally.

a)          When the cell density reaches 1.5 - 2E6 cells/mL, subculture the cells. Do not allow the cell density to exceed 2E6 cells/mL.

b)         It is recommended to use T-25 flasks for subculturing.

c)          These cells are suspension cells, and it is recommended to use the "half-medium change" method to maintain optimal cell conditions during passaging.

d)         During passaging, you can directly add fresh growth medium to the culture flask, gently pipette to resuspend the cells, and then transfer the cell suspension to a new T-25 flask for continued culture.

Subcultivation Ratio: Maintain cultures at a cell concentraion between 3E5 and 1E6 viable cells/mL.

Medium Renewal: Every 2 to 3 days

Notes

a)          These cells are sensitive to density, so please ensure that the cell density is maintained within an appropriate range during culture and subculturing.

b)         During the first passage, pay attention to the nutrient supply; if not subculturing, make sure to add fresh recovery medium every other day as needed.

Message Consultation
If you have more questions, please fill in the relevant information,we'll respond as soon as possible to assist you!
Reset
Submit
You can also contact us on the Scientist and Science Exchange marketplaces.
Current Position:Product Center > Cell lines > Immune checkpoints > CD40 > H_CD40(TNFRSF5) Reporter Jurkat Cell Line
classify
H_CD40(TNFRSF5) Reporter Jurkat Cell Line
Description
Cat. No: GM-C09520
Product: H_CD40(TNFRSF5) Reporter Jurkat Cell Line


CD40 is a key cell surface receptor in the TNF receptor superfamily, primarily found on B cells, dendritic cells, macrophages, and some endothelial cells. Its main role is to regulate immune responses by promoting B cell proliferation, differentiation, and antibody production. When it binds to its ligand CD40L (expressed by activated T cells), CD40 activates various signaling pathways that enhance immune function.

CD40 signaling occurs through multiple pathways activated upon CD40L binding, including NF-Κb, MAPK (ERK, JNK, p38 MAPK), and PI3K/Akt. This activation triggers biological responses such as cell proliferation, survival, cytokine secretion, and immune memory formation, making CD40 crucial for regulating immune responses and maintaining immune tolerance.

H_CD40(TNFRSF5) Reporter Jurkat Cell Line is a clonal stable Jurkat cell line constructed using lentiviral technology, constitutive expression of the CD40 gene, along with signal-dependent expression of a luciferase reporter gene. When CD40L binds to CD40, it activates downstream signaling pathways, leading to the expression of luciferase. Blockade antibodies can inhibit this signal transmission. The luciferase activity measurement indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of drugs related to CD40.
Data
Response to Human CD40L Protein. The H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well (96-well format) was stimulated with serial dilutions of Human CD40L Protein (Cat. GM-84919RP) in assay buffer (RPMI 1640 + 1% FBS + 1% P.S) for 6 hours. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The maximum induction fold was approximately [71.7]. Data are shown by drug mass concentration.
Response to Anti-H_CD40L hIgG1 Antibody(dapirolizumab). Serial dilutions of Anti-H_CD40L hIgG1 Antibody(dapirolizumab) (Cat. GM-83977AB) was incubated with 100 ng/well of Human CD40L Protein (Cat. GM-84919RP) for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). After pre-incubation, add the mixture to the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a density of 1E5 cells/well in a 96-well format, and incubate for 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The results indicated maximum blocking folds of approximately [61.2]. Data are shown by drug mass concentration.
Response to Anti-H_CD40L hIgG1 Antibody(dapirolizumab). Serial dilutions of the Anti-H_CD40L hIgG1 Antibody(dapirolizumab) (Cat. GM-83977AB) was incubated with 1E4 cells/well of the H_CD40L CHO-K1 Cell Line (Cat. GM-C35532) in a 96-well plate for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). Subsequently, the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well was added, and the coculture proceeded for an additional 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The results indicated maximum blocking folds of approximately [45.2]. Data are shown by drug mass concentration.
Response to Anti-H_CD40 hIgG1 Antibody(ravagalimab). Serial dilutions of the Anti-H_CD40 hIgG1 Antibody(ravagalimab) (Cat. GM-86199AB) was incubated with 1E5 cells/well of the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) in a 96-well plate for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). Subsequently, the Human CD40L Protein (Cat. GM-84919RP) at a concentration of 50 ng/well was added, and the coculture proceeded for an additional 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The results indicated maximum blocking folds of approximately [14.3]. Data are shown by drug mass concentration.
Response to Anti-H_CD40 hIgG1 Antibody(ravagalimab). H_CD40L CHO-K1 Cell Line (Cat. GM-C35532) was seeded at a density of 1E4 cells per well in a 96-well plate and incubated overnight. The next day, serial dilutions of the Anti-H_CD40 hIgG1 Antibody(ravagalimab) (Cat. GM-86199AB) were incubated with 1E5 cells/well of the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) in a 96-well plate for 1 hour, and then added to the pre-seeded cells. The mixture was incubated for an additional 6 hours. Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The results indicated maximum blocking folds of approximately [41.3]. Data are shown by drug mass concentration
Response to Anti-H_CD40 hIgG1 Antibody(APX005M). The H_FCGR2B (CD32B) CHO-K1 Cell Line (Cat. GM-C16925) and the CHO-K1 Cell Line were seeded at a density of 1E4 cells per well in a 96-well plate and incubated overnight. The next day, serial dilutions of Anti-H_CD40 hIgG1 Antibody(APX005M) Cat. GM-24025AB) and the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells per well were added to the pre-seeded cells. The mixture was incubated for an additional 6 hours. Firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The maximum induction fold was approximately [50.5 and 6.7]. Data are presented based on drug mass concentration.
The passage stability of response to Human CD40L Protein. The passage 4, 14 and 24 of H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well (96-well format) were stimulated with serial dilutions of Human CD40L Protein (Cat. GM-84919RP) in assay buffer (RPMI 1640 + 1% FBS + 1% P.S) for 6 hours. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). Data are shown by drug mass concentration.
H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) was determined by flow cytometry using Anti-H_CD40 hIgG1 Antibody(APX005M) (Cat. GM-24025AB).
H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) was determined by flow cytometry using Anti-H_CD40L hIgG1 Antibody(dapirolizum) (Cat. GM-83977AB).
Specifications
Cat. NoGM-C09520
ProductH_CD40(TNFRSF5) Reporter Jurkat Cell Line
Product Format1 vial of frozen cells
Quantity5E6 Cells per vial,1 mL
Storage ConditionsLiquid nitrogen immediately upon receipt
Recovery MediumRPMI 1640 +10% FBS +1% P.S
Growth mediumRPMI 1640 +10% FBS +1% P.S+3.5 μg/mL Blastincidin+0.75 μg/mL Puromycin
NoteNone
Freezing Medium90%FBS+10% DMSO
Growth propertiesSuspension
Growth Conditions37°C, 5% CO₂
Safety considerationsBiosafety Level 2
Mycoplasma TestingThe cell line has been screened to confirm the absence of Mycoplasma species.
Materials
ReagentOrdering Information
RPMI 1640VivaCell/C3010-0500
Fetal Bovine SerumCegrogen biotech/A0500-3010
Pen/StrepThermo/15140-122
BlasticidinGenomeditech/GM-040404
PuromycinGenomeditech/GM-040401
H_CD40L CHO-K1 Cell LineGenomeditech/GM-C35532
H_FCGR2B(CD32B) CHO-K1 Cell LineGenomeditech/GM-C16925
Human CD40L Protein; His TagGenomeditech/GM-84919RP
Anti-H_CD40L hIgG1 Antibody(dapirolizumab)Genomeditech/GM-83977AB
Anti-H_CD40 hIgG1 Antibody(ravagalimab)Genomeditech/GM-86199AB
Anti-H_CD40 hIgG1 Antibody(APX005M)Genomeditech/GM-24025AB
GMOne-Step Luciferase Reporter Gene Assay KitGenomeditech/GM-040503
Cell Culture

Cell Recovery

Recovery Medium: RPMI 1640 +10% FBS +1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium. And spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend cell pellet with the recommended complete medium. And dispense the suspension into 1 - 2 T-25 culture flasks.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90%FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: RPMI 1640 +10% FBS +1% P.S+3.5 μg/mL Blastincidin+0.75 μg/mL Puromycin

Approximately 48-72 hours after the initial thawing, the cells can be passaged for the first time. After this initial passage, the culture medium can be adjusted to growth medium supplemented with antibiotics. If cells are not passaged within 48 hours, it is recommended to add some fresh recovery medium and place the flask horizontally.

a)          When the cell density reaches 1.5 - 2E6 cells/mL, subculture the cells. Do not allow the cell density to exceed 2E6 cells/mL.

b)         It is recommended to use T-25 flasks for subculturing.

c)          These cells are suspension cells, and it is recommended to use the "half-medium change" method to maintain optimal cell conditions during passaging.

d)         During passaging, you can directly add fresh growth medium to the culture flask, gently pipette to resuspend the cells, and then transfer the cell suspension to a new T-25 flask for continued culture.

Subcultivation Ratio: Maintain cultures at a cell concentraion between 3E5 and 1E6 viable cells/mL.

Medium Renewal: Every 2 to 3 days

Notes

a)          These cells are sensitive to density, so please ensure that the cell density is maintained within an appropriate range during culture and subculturing.

b)         During the first passage, pay attention to the nutrient supply; if not subculturing, make sure to add fresh recovery medium every other day as needed.

Message Consultation
If you have more questions, please fill in the relevant information,we'll respond as soon as possible to assist you!
Reset
Submit
You can also contact us on the Scientist and Science Exchange marketplaces.
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit